Ovid Therapeutics (OVID) Net Income towards Common Stockholders (2016 - 2026)

Ovid Therapeutics (OVID) has reported Net Income towards Common Stockholders for 11 consecutive years, with -$15.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Income towards Common Stockholders fell 220.43% year-over-year to -$15.0 million; the trailing twelve-month figure through Jun 2026 stood at -$34.5 million (up 9.65% YoY), and the FY2025 full-year result was -$17.4 million, up 34.12% from the prior year.
• Net Income towards Common Stockholders grew to -$15.0 million in Q2 2026 per OVID's latest filing, from -$17.0 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $9.7 million in Q4 2025 and bottomed at -$17.0 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$10.1 million across 5 years, with a median of -$12.1 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Net Income towards Common Stockholders jumped 204.43% in 2025, then plunged 220.43% in 2026.
• Over 5 years, Net Income towards Common Stockholders stood at -$11.5 million in 2022, then tumbled by 33.18% to -$15.3 million in 2023, then surged by 39.61% to -$9.3 million in 2024, then surged by 204.43% to $9.7 million in 2025, then slumped by 255.32% to -$15.0 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$15.0 million, -$17.0 million, and $9.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.